Literature DB >> 10233418

Human myeloma cells express the CD38 ligand CD31.

A Vallario1, M Chilosi, F Adami, L Montagna, S Deaglio, F Malavasi, F Caligaris-Cappio.   

Abstract

Multiple myeloma (MM) plasma cells (PC) are CD38+. A ligand for CD38 is the adhesion molecule CD31. By flow cytometry and immunocytochemistry we have investigated whether malignant PC co-express CD38 and CD31. All 68 patients studied were CD38+. 14/14 monoclonal gammopathies of undetermined significance (MGUS) and 39/39 plasmacytic MM patients co-expressed CD38 and CD31 at high density. Only 1/11 plasmablastic MM and 1/4 plasma cell leukaemias (PCL) expressed CD31. These data indicated that PC malignancies co-expressed high levels of both CD38 and its ligand CD31, with the exception of plasmablastic MM and PCL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233418

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  NAD+ metabolism and its roles in cellular processes during ageing.

Authors:  Anthony J Covarrubias; Rosalba Perrone; Alessia Grozio; Eric Verdin
Journal:  Nat Rev Mol Cell Biol       Date:  2020-12-22       Impact factor: 94.444

Review 2.  New insights into role of microenvironment in multiple myeloma.

Authors:  Guido J Tricot
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 3.  Immunotherapies targeting CD38 in Multiple Myeloma.

Authors:  Djordje Atanackovic; Mary Steinbach; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

4.  Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.

Authors:  Kah-Whye Peng; Ahmet Dogan; Julie Vrana; Chunsheng Liu; Hooi T Ong; Shaji Kumar; Angela Dispenzieri; Allan B Dietz; Stephen J Russell
Journal:  Am J Hematol       Date:  2009-07       Impact factor: 10.047

5.  Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation.

Authors:  Federica Costa; Denise Toscani; Antonella Chillemi; Valeria Quarona; Marina Bolzoni; Valentina Marchica; Rosanna Vescovini; Cristina Mancini; Eugenia Martella; Nicoletta Campanini; Chiara Schifano; Sabrina Bonomini; Fabrizio Accardi; Alberto L Horenstein; Franco Aversa; Fabio Malavasi; Nicola Giuliani
Journal:  Oncotarget       Date:  2017-05-16

Review 6.  CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents.

Authors:  Federica Costa; Benedetta Dalla Palma; Nicola Giuliani
Journal:  Cells       Date:  2019-12-13       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.